BPC applauds FDA for recognizing in its final guidance that each biological product needs a distinguishable non-proprietary name, including previously approved originator drugs. Distinguishable names for biological products foster pharmacovigilance through a detailed ability to track adverse events, a necessary step to preserve patient safety. FDA’s final guidance states that all biological products will bear a nonproprietary name that is a combination of a core name and a four-letter suffix, devoid of meaning. However, as BPC has voiced previously, biologics prescribers tell us that the suffix should be memorable, which cannot be easily accomplished when it is meaningless. We remain concerned that randomized four-letter codes may complicate the achievement of FDA’s goal to facilitate pharmacovigilance and prevent inadvertent substitution. In addition, interchangeable biosimilars should be assigned distinguishable names. Additional perspective on this issue provided in our related material.
February 13, 2017 Physician Groups on FDA Biologics Naming Guidance; Disappointed in ‘Random’ Suffix
January 12, 2017 BPC Statement Applauding FDA for Distinguishable Biologics Naming; Disappointed in ‘Random’ Suffix
October 27, 2015 Physician Groups Applaud FDA for Distinguishable Naming; But Argue Against ‘Random’ Suffix
Stay Informed View the latest newsletter
To receive regular newsletters and periodic alerts from the BPC, enter your email address in the form below: